New Document Guides Clinical Decision-Making on Atopic Dermatitis Treatment
A recent review has found that high-dose upadacitinib is among the most effective therapies for addressing multiple outcomes in moderate-to-severe atopic dermatitis (AD), but is also among the most harmful. High-dose abrocitinib and low-dose upadacitinib are effective, but also among the most harmful.